Avanos (AVNS) Medical announced the divestiture of its Hyaluronic Acid product line to Channel-Markers Medical, a privately held company based in Raleigh, NC. The divested portfolio includes the TriVisc and GenVisc 850 injection products, which are indicated for the treatment of osteoarthritis pain in the knee. These injectable HA therapies are designed to help patients manage OA symptoms and improve joint function. With this announcement, ownership of Avanos’ HA product line has officially transferred to CMM. Avanos will provide transition support through the end of 2025 to ensure uninterrupted service and support for customers, partners, and patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVNS: